Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

By Yahoo! Finance | Oct 30, 2024 at 03:27 AM EST

BMN 333 aims to enhance CNP's half-life for improved effects in skeletal disorders. The trial length and expansion into other indications are flexible based on data. Factors impacting financials include inventory reserves and growth strategies for products like Palynziq and Voxzogo.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.